GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GW Pharmaceuticals PLC (NAS:GWPH) » Definitions » Total Current Liabilities

GW Pharmaceuticals (GW Pharmaceuticals) Total Current Liabilities : $160.2 Mil (As of Mar. 2021)


View and export this data going back to 2013. Start your Free Trial

What is GW Pharmaceuticals Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. GW Pharmaceuticals's total current liabilities for the quarter that ended in Mar. 2021 was $160.2


GW Pharmaceuticals Total Current Liabilities Historical Data

The historical data trend for GW Pharmaceuticals's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GW Pharmaceuticals Total Current Liabilities Chart

GW Pharmaceuticals Annual Data
Trend Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Dec19 Dec20
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.54 44.91 58.67 117.56 159.81

GW Pharmaceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 103.47 118.50 140.29 159.81 160.25

GW Pharmaceuticals Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

GW Pharmaceuticals's Total Current Liabilities for the fiscal year that ended in Dec. 2020 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=115.766+7.212
+Other Current Liabilities+Current Deferred Liabilities
=36.828+0
=159.8

GW Pharmaceuticals's Total Current Liabilities for the quarter that ended in Mar. 2021 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=127.43+6.963
+Other Current Liabilities+Current Deferred Liabilities
=25.853+0
=160.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


GW Pharmaceuticals Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of GW Pharmaceuticals's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


GW Pharmaceuticals (GW Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Sovereign House, Chivers Way, Vision Park, Histon, Cambridge, GBR, CB24 9BZ
GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.
Executives
Douglas B. Snyder officer: Chief Legal Officer SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB249BZ
Volker Knappertz officer: Chief Medical Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB249BZ
Cabot Brown director SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Adam D. George officer: Secretary SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Guy Geoffrey W Dr director, officer: Executive Chairman ETHICAL HOLDINGS PLC CORPUS CHRISTI HOUSE 9 WEST STREET GODMANCHESTER CAMBRIDGESHIRE PE18 A1
Christopher J. Tovey officer: Chief Operating Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Justin D. Gover director, officer: Chief Executive Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
James Noble director C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Alicia Secor director 33 HAYDEN AVE., LEXINGTON MA 02421
Darren S Cline officer: U.S. Chief Commercial Officer 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
William A. Waldegrave director SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Scott M. Giacobello officer: Chief Financial Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Julian S Gangolli officer: President, North America 4955 BASELINE AVENUE, SANTA YNEZ CA 93460

GW Pharmaceuticals (GW Pharmaceuticals) Headlines

From GuruFocus